Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Shares of Omega Diagnostics Group Plc (LON: ODX) rallied 5.23% after the UK Rapid Test Consortium (UK-RTC), a group of UK diagnostics firms, presented new data regarding the effectiveness of the AbC-19TM rapid antibody test manufactured by the consortium.
According to a study done at Birmingham University on people who had received a single dose of the Pfizer-BioNTech COVID-19 vaccine, the AbC-19TM rapid antibody test measured patients' immune response after the first dose of the vaccine.
The test also isolated different immune responses in people previously infected by the virus and people with no prior infection history.
Omega Diagnostics shares spiked higher following the announcement, given that the shares soared last week after the medical diagnostics company hinted at today’s results in a classic buy the rumour sell the news story.
The AbC-19 lateral flow test proved to have the highest accuracy in Public Health England tests compared to three other rapid tests in a study conducted on a single group of participants.
Omega Diagnostics is expected to report annual earnings of £9.3 million for 2020 after halting its work on allergy medications last year to focus on COVID-19 tests, which cost the firm about £8.73 million.
The UK-RTC issued a statement saying: “The initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination. Should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the AbC-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings.”
Omega Diagnostics share price.
Omega Diagnostics shares rallied 5.23% to trade at 90.5p after rising from Wednesday’s closing price of 86p.
Should you invest in Omega Diagnostics shares? Omega Diagnostics shares are traded on the AIM market of the London stock exchange (the alternative investment market) which is the sub market specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Omega shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .